Breaking News

Current COVID-19 Antibody Cocktails Could Be Defused by Omicron Variant

November 30, 2021 • 8:33 am CST
(Coronavirus Today)

New York-based Regeneron Inc. announced today there had been no direct data testing the Omicron variant's resistance to monoclonal antibody-conveyed immunity.

However, the company is currently evaluating REGEN-COV® (casirivimab and imdevimab) against the Omicron (B.1.1.529) variant.

 The current U.S. Food and Drug Administration (FDA) Fact Sheet and multiple separate analyses, including a publication in Cell, affirm that REGEN-COV retains potency against the main variants of concern, including Delta, which remains the predominant strain in the U.S. today.

This information is integrated into the REGEN-COV overview.

'It is important that high-risk patients who are diagnosed with COVID-19 are aware of current authorized treatment options and seek out these therapies early in the course of their infection,' stated Regeneron's press statement issued on November 30, 2021.

Regeneron has one of the largest collections of fully human monoclonal antibodies targeting the SARS-CoV-2 betacoronavirus.

The first of these additional investigational candidates have already entered into clinical trials, with others nearing clinic readiness.

Preliminary analyses suggest that several of these next-generation antibodies may have the potential to retain activity against the Omicron variant and the other existing variants of concern. Further in vitro data is expected over the next month.

Breaking antibody treatment news is published on this Coronavirus Today webpage.